Gilead Sciences Q2 FY2026 Earnings Call Summary

GILD NASDAQ Healthcare 📅 2026-08-04 ⏱ ~60 sec read 🟡 Neutral

⏱️ 60-Second Brief Gilead Sciences · Q2 FY2026

Stock Next Day

▼ 2.98%

$135.25 → $131.22

Revenue

$7.8B

EPS

$(8.45)

AI Sentiment

🟡 Neutral

The company demonstrated robust underlying revenue growth an…

📌 Bottom Line: Gilead Sciences reported a robust 10% year-over-year revenue increase, driven by strong performance in its HIV portfolio and key oncology and liver disease products, but recorded a substantial net loss of $(10.5) billion…

🤖 AI-Assisted Summary — Produced using a custom AI pipeline by Abhi, reviewed for accuracy. · ⚠️ Not financial advice. For informational purposes only. Full Disclaimer →

✍️ EarningsBloom Editorial Team · 📅 Last updated: 2026-08-05 · 📎 Source: SEC EDGAR / Company Press Release

📋 TL;DR — What Happened

Gilead Sciences reported a robust 10% year-over-year revenue increase, driven by strong performance in its HIV portfolio and key oncology and liver disease products, but recorded a substantial net loss of $(10.5) billion due to significant acquired in-process research and development (IPR&D) expenses. This quarter highlights the company's underlying operational strength and pipeline expansion efforts, even as large strategic investments heavily impact short-term profitability.

📊 Key Financial Metrics

Revenue $7.8B

EPS (Diluted) $(8.45)

YoY Revenue Growth 10%

Gross Margin 79.3%

Net Income $(10.5B)

AI Sentiment 🟡 Neutral The company demonstrated robust underlying revenue growth and significant pipeline advancements, but these positives were heavily overshadowed by substantial acquisition-related research and development expenses leading to a significant net loss and cash reduction.

✅ What Went Well

✅ **Exceptional Base Business Growth:** Gilead achieved a 10% year-over-year increase in product sales excluding Veklury, reaching $7.6 billion, demonstrating robust demand across its core therapeutic areas, particularly HIV, Trodelvy, and Livdelzi.

✅ **Dominant HIV Franchise Performance:** The HIV portfolio delivered impressive growth, with sales climbing 12% to $5.7 billion. This was significantly driven by Biktarvy, which saw a 7% increase to $3.8 billion, and Descovy, which surged 48% to $967 million, reflecting strong market penetration and pricing.

✅ **Significant Clinical and Regulatory Milestones:** The company secured three FDA approvals, including the first and only FDA-approved treatment for chronic HDV (Hepcludex) and an expanded indication for Trodelvy in first-line metastatic triple-negative breast cancer. Additionally, three Phase 3 trials reported positive updates, underscoring a productive R&D engine.

⚠️ Concerns & Risks

⚠️ **Substantial Net Loss and EPS Impact:** The most prominent concern is the reported net loss of $(10.5) billion and diluted EPS of $(8.45), primarily due to $11.2 billion in acquired IPR&D expenses. While these are non-cash accounting charges for future investments, they significantly impact reported profitability and investor sentiment.

⚠️ **Significant Cash Outflow and Reduced Liquidity:** The company's cash, cash equivalents, and marketable debt securities plummeted from $10.6 billion to $3.2 billion, largely due to $11.3 billion in cash outflows for acquisitions. This substantial reduction in liquidity could limit future financial flexibility without additional financing.

⚠️ **Underperformance in Key Segments and R&D Setbacks:** Veklury sales decreased sharply by 81% to $23 million due to lower COVID-19 hospitalizations, and Cell Therapy product sales declined 14% to $417 million amidst competitive headwinds. Furthermore, the discontinuation of the Phase 3 EVOKE-03 study for Trodelvy in non-small cell lung cancer represents a setback in a promising oncology indication.

🔮 CEO / Management Guidance

CEO Daniel O’Day expressed confidence in the company's performance, stating that the strong second quarter, driven by the HIV portfolio, Trodelvy, and Livdelzi, supports an increase in base business revenue expectations for 2026. For the full year 2026, Gilead updated its product sales guidance to $30.1 billion to $30.4 billion and raised its product sales excluding Veklury guidance to $29.8 billion to $30.1 billion, while also adjusting its diluted loss per share guidance to $(3.75) to $(3.40) to reflect the significant IPR&D charges.

💬 Key Quote

Gilead delivered a very strong second quarter, with 10% year-over-year revenue growth in our base business driven by our HIV portfolio, Trodelvy and Livdelzi. HIV sales grew 12%, reflecting continued strength in treatment and the rapid expansion of our PrEP business, supporting an increase in our base business revenue expectations for 2026. — Daniel O’Day, Chairman and Chief Executive Officer

📅 Quarter-over-Quarter Comparison

Comparing Q2 FY2026 vs Q1 FY2026 All quarters →

Revenue $6.96B → $7.8B

EPS $1.06 → $(8.45)

Gross Margin 79.2% → 79.3%

Net Income $2.021B → $(10.5B)

YoY Growth 4% → 10%

Sentiment 🟡 Neutral → 🟡 Neutral

Stock Reaction -1.96% → -2.98%

🏢 About Gilead Sciences

Gilead Sciences (GILD) is a publicly listed company on the NASDAQ exchange in the Healthcare sector. EarningsBloom tracks its quarterly earnings calls to provide free AI-generated summaries for investors.

GILD NASDAQ Healthcare All Gilead Sciences Summaries →

📈 Want to act on this insight?

🇮🇳 Open Zerodha Account 🌱 Start with Groww 📄 Full Transcript on Seeking Alpha 📚 Learn Financial Analysis

Topics: HIV Portfolio Growth Strategic Acquisitions & R&D Oncology Pipeline Developments Financial Performance & Liquidity

📁 More from Gilead Sciences

View all earnings summaries for Gilead Sciences →